Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry

Cell Cycle

Volumn 15, Issue 5, 2016, Pages 730-739

  Parsels, Leslie A ^a   Tanska, Daria M ^a   Parsels, Joshua D ^a   Zabludoff, Sonya D ^b,c   Cuneo, Kyle C ^a   Lawrence, Theodore S ^a   Maybaum, Jonathan ^a   Morgan, Meredith A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Zabludoff Consulting   (United States)

Author keywords

aberrant mitotic entry; AZD7762; checkpoint abrogation; CHK1; gemcitabine; pancreatic cancer

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; CHECKPOINT KINASE 1; CYCLIN B1; GEMCITABINE; HISTONE H2AX; HISTONE H3; PURVALANOL A; ROSCOVITINE; SERINE; SMALL INTERFERING RNA; 3-(CARBAMOYLAMINO)-5-(3-FLUOROPHENYL)-N-(3-PIPERIDYL)THIOPHENE-2-CARBOXAMIDE; ANTINEOPLASTIC ANTIMETABOLITE; CCNB1 PROTEIN, HUMAN; CHEK1 PROTEIN, HUMAN; DEOXYCYTIDINE; NOCODAZOLE; THIOPHENE DERIVATIVE; UREA;

ARTICLE; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; ENZYME INHIBITION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MITOSIS; PANCREATIC CANCER CELL LINE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DNA DAMAGE; DRUG SCREENING; METABOLISM; PANCREATIC NEOPLASMS; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CHECKPOINT KINASE 1; CYCLIN B1; DEOXYCYTIDINE; DNA DAMAGE; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MITOSIS; NOCODAZOLE; PANCREATIC NEOPLASMS; THIOPHENES; UREA;

EID: 84962005505     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2016.1148841     Document Type: Article

References (45)

1. T.Conroy, F.Desseigne, M.Ychou, O.Bouche, R.Guimbaud, Y.Becouarn, A.Adenis, J.L.Raoul, S.Gourgou-Bourgade, C.de la Fouchardiere, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25; PMID:21561347; http://dx.doi.org/10.1056/NEJMoa1011923
2. D.D.Von Hoff, R.K.Ramanathan, M.J.Borad, D.A.Laheru, L.S.Smith, T.E.Wood, R.L.Korn, N.Desai, V.Trieu, J.L.Iglesias, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29:4548-54; PMID:21969517; http://dx.doi.org/10.1200/JCO.2011.36.5742
3. C.X.Ma, J.W.Janetka, H.Piwnica-Worms. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2010; PMID:21087899
4. C.S.Sorensen, R.G.Syljuasen, J.Falck, T.Schroeder, L.Ronnstrand, K.K.Khanna, B.B.Zhou, J.Bartek, J.Lukas. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003; 3:247-58; PMID:12676583; http://dx.doi.org/10.1016/S1535-6108(03)00048-5
5. M.J.O’Connell, J.M.Raleigh, H.M.Verkade, P.Nurse. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997; 16:545-54; PMID:9034337; http://dx.doi.org/10.1093/emboj/16.3.545
6. L.M.Karnitz, K.S.Flatten, J.M.Wagner, D.Loegering, J.S.Hackbarth, S.J.Arlander, B.T.Vroman, M.B.Thomas, Y.U.Baek, K.M.Hopkins, et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 2005; 68:1636-44; PMID:16126823
7. M.A.Morgan, L.A.Parsels, J.D.Parsels, A.K.Mesiwala, J.Maybaum, T.S.Lawrence. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 2005; 65:6835-42; PMID:16061666; http://dx.doi.org/10.1158/0008-5472.CAN-04-2246
8. B.Ewald, D.Sampath, W.Plunkett. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 2007; 6:1239-48; PMID:17406032; http://dx.doi.org/10.1158/1535-7163.MCT-06-0633
9. C.S.Sorensen, L.T.Hansen, J.Dziegielewski, R.G.Syljuasen, C.Lundin, J.Bartek, T.Helleday. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195-201; PMID:15665856; http://dx.doi.org/10.1038/ncb1212
10. R.G.Syljuasen, C.S.Sorensen, L.T.Hansen, K.Fugger, C.Lundin, F.Johansson, T.Helleday, M.Sehested, J.Lukas, J.Bartek. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005; 25:3553-62; PMID:15831461; http://dx.doi.org/10.1128/MCB.25.9.3553-3562.2005
11. R.Thompson, A.Eastman. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact clinical trial design. Br J Clin Pharmacol 2013; 76:358-69.
12. E.Petermann, M.Woodcock, T.Helleday. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci U S A 2010; 107:16090-5; PMID:20805465; http://dx.doi.org/10.1073/pnas.1005031107
13. L.A.Parsels, M.A.Morgan, D.M.Tanska, J.D.Parsels, B.D.Palmer, R.J.Booth, W.A.Denny, C.E.Canman, A.J.Kraker, T.S.Lawrence, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009; 8:45-54; PMID:19139112; http://dx.doi.org/10.1158/1535-7163.MCT-08-0662
14. D.J.Matthews, F.M.Yakes, J.Chen, M.Tadano, L.Bornheim, D.O.Clary, A.Tai, J.M.Wagner, N.Miller, Y.D.Kim, et al. Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo. Cell Cycle 2007; 6:104-10; PMID:17245119; http://dx.doi.org/10.4161/cc.6.1.3699
15. A.I.Daud, M.T.Ashworth, J.Strosberg, J.W.Goldman, D.Mendelson, G.Springett, A.P.Venook, S.Loechner, L.S.Rosen, F.Shanahan, et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol 2015; 33:1060-6; PMID:25605849; http://dx.doi.org/10.1200/JCO.2014.57.5027
16. M.A.Morgan, T.S.Lawrence. Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res 2015; 21:2898-904; PMID:26133775; http://dx.doi.org/10.1158/1078-0432.CCR-13-3229
17. E.Sausville, P.Lorusso, M.Carducci, J.Carter, M.F.Quinn, L.Malburg, N.Azad, D.Cosgrove, R.Knight, P.Barker, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73:539-49; PMID:24448638; http://dx.doi.org/10.1007/s00280-014-2380-5
18. S.McNeely, R.Beckmann, A.K.Bence Lin CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther 2014; 142:1-10; PMID:24140082; http://dx.doi.org/10.1016/j.pharmthera.2013.10.005
19. M.A.Morgan, L.A.Parsels, J.D.Parsels, T.S.Lawrence, J.Maybaum. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 2006; 5:1983-8; PMID:16931916; http://dx.doi.org/10.4161/cc.5.17.3184
20. L.A.Parsels, Y.Qian, D.M.Tanska, M.Gross, L.Zhao, M.C.Hassan, S.Arumugarajah, J.D.Parsels, L.Hylander-Gans, D.M.Simeone, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 2011; 17:3706-15; PMID:21482692; http://dx.doi.org/10.1158/1078-0432.CCR-10-3082
21. S.McNeely, C.Conti, T.Sheikh, H.Patel, S.Zabludoff, Y.Pommier, G.Schwartz, A.Tse. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010; 9:995-1004; PMID:20160494; http://dx.doi.org/10.4161/cc.9.5.10935
22. R.Rawlinson, A.J.Massey. gammaH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments. BMC Cancer 2014; 14:483; PMID:24996846; http://dx.doi.org/10.1186/1471-2407-14-483
23. J.Yuan, R.Adamski, J.Chen. Focus on histone variant H2AX: to be or not to be. FEBS Lett 2010; 584:3717-24; PMID:20493860; http://dx.doi.org/10.1016/j.febslet.2010.05.021
24. M.Aarts, I.Bajrami, M.T.Herrera-Abreu, R.Elliott, R.Brough, A.Ashworth, C.J.Lord, N.C.Turner. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways. Mol Cancer Ther 2015; 14:865-76; PMID:25673822; http://dx.doi.org/10.1158/1535-7163.MCT-14-0845
25. M.E.Gagou, P.Zuazua-Villar, M.Meuth. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell 2010; 21:739-52; PMID:20053681; http://dx.doi.org/10.1091/mbc.E09-07-0618
26. X.Huang, T.Tran, L.Zhang, R.Hatcher, P.Zhang. DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint. Proc Natl Acad Sci U S A 2005; 102:1065-70; PMID:15650047; http://dx.doi.org/10.1073/pnas.0409130102
27. M.A.Morgan, L.A.Parsels, L.Zhao, J.D.Parsels, M.A.Davis, M.C.Hassan, S.Arumugarajah, L.Hylander-Gans, D.Morosini, D.M.Simeone, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972-81; PMID:20501833; http://dx.doi.org/10.1158/0008-5472.CAN-09-3573
28. C.G.Engelke, L.A.Parsels, Y.Qian, Q.Zhang, D.Karnak, J.R.Robertson, D.M.Tanska, D.Wei, M.A.Davis, J.D.Parsels, et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res 2013; 19:4412-21; PMID:23804422; http://dx.doi.org/10.1158/1078-0432.CCR-12-3748
29. A.Lindqvist, V.Rodriguez-Bravo, R.H.Medema. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol 2009; 185:193-202; PMID:19364923; http://dx.doi.org/10.1083/jcb.200812045
30. J.Scorah, C.H.McGowan. Claspin and Chk1 regulate replication fork stability by different mechanisms. Cell Cycle 2009; 8:1036-43; PMID:19270516; http://dx.doi.org/10.4161/cc.8.7.8040
31. B.B.Zhou, J.Bartek. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4:216-25; PMID:14993903; http://dx.doi.org/10.1038/nrc1296
32. M.Aarts, R.Sharpe, I.Garcia-Murillas, H.Gevensleben, M.S.Hurd, S.D.Shumway, C.Toniatti, A.Ashworth, N.C.Turner. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012; 2:524-39; PMID:22628408; http://dx.doi.org/10.1158/2159-8290.CD-11-0320
33. C.King, H.Diaz, D.Barnard, D.Barda, D.Clawson, W.Blosser, K.Cox, S.Guo, M.Marshall. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs 2014; 32:213-26; PMID:24114124; http://dx.doi.org/10.1007/s10637-013-0036-7
34. C.Feijoo, C.Hall-Jackson, R.Wu, D.Jenkins, J.Leitch, D.M.Gilbert, C.Smythe. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001; 154:913-23; PMID:11535615; http://dx.doi.org/10.1083/jcb.200104099
35. S.B.Koh, A.Courtin, R.J.Boyce, R.G.Boyle, F.M.Richards, D.I.Jodrell. CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus. Cancer Res 2015; 75:3583-95; PMID:26141863; http://dx.doi.org/10.1158/0008-5472.CAN-14-3347
36. C.King, H.B.Diaz, S.McNeely, D.Barnard, J.Dempsey, W.Blosser, R.Beckmann, D.Barda, M.S.Marshall. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther 2015; 14:2004-13; PMID:26141948; http://dx.doi.org/10.1158/1535-7163.MCT-14-1037
37. L.I.Toledo, M.Altmeyer, M.B.Rask, C.Lukas, D.H.Larsen, L.K.Povlsen, S.Bekker-Jensen, N.Mailand, J.Bartek, J.Lukas. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013; 155:1088-103; PMID:24267891; http://dx.doi.org/10.1016/j.cell.2013.10.043
38. H.Beck, V.Nahse-Kumpf, M.S.Larsen, K.A.O’Hanlon, S.Patzke, C.Holmberg, J.Mejlvang, A.Groth, O.Nielsen, R.G.Syljuasen, et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 2012; 32:4226-36; PMID:22907750; http://dx.doi.org/10.1128/MCB.00412-12
39. S.D.Zabludoff, C.Deng, M.R.Grondine, A.M.Sheehy, S.Ashwell, B.L.Caleb, S.Green, H.R.Haye, C.L.Horn, J.W.Janetka, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-66; PMID:18790776; http://dx.doi.org/10.1158/1535-7163.MCT-08-0492
40. L.M.Karnitz, L.Zou. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res 2015; 21:4780-5; PMID:26362996
41. J.G.Glanzer, S.Liu, L.Wang, A.Mosel, A.Peng, G.G.Oakley. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res 2014; 74:5165-72; PMID:25070753; http://dx.doi.org/10.1158/0008-5472.CAN-14-0306
42. T.Kausar, J.S.Schreiber, D.Karnak, L.A.Parsels, J.D.Parsels, M.A.Davis, L.Zhao, J.Maybaum, T.S.Lawrence, M.A.Morgan. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Neoplasia 2015; 17:757-66; PMID:26585231; http://dx.doi.org/10.1016/j.neo.2015.09.006
43. X.Huang, H.D.Halicka, Z.Darzynkiewicz. Detection of histone H2AX phosphorylation on Ser-139 as an indicator of DNA damage (DNA double-strand breaks). Curr Protoc Cytom 2004; Chapter 7, Unit 7 27.1-27.7; PMID:18770804
44. T.S.Lawrence Ouabain sensitizes tumor cells but not normal cells to radiation. Int J Radiat Oncol Biol Phys 1988; 15:953-8; PMID:3182336; http://dx.doi.org/10.1016/0360-3016(88)90132-0
45. M.A.Morgan, L.A.Parsels, L.E.Kollar, D.P.Normolle, J.Maybaum, T.S.Lawrence. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008; 14:5142-9; PMID:18698032; http://dx.doi.org/10.1158/1078-0432.CCR-07-4072